{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-033885","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.655302+00:00","generated_at":"2026-05-15T09:10:04.521791+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fennec posts record FY2025 PEDMARK sales $44.6M (+50% YoY); Q4 $13.8M (+75%)","bullets":["Full-year net product sales $44.6M vs $29.6M in 2024; Q4 $13.8M vs $7.9M in prior year.","Net loss $10.1M in FY2025 vs $0.4M in 2024, driven by higher G&A and a $2.0M loss on debt extinguishment.","Cash $36.7M at year-end; zero debt after paying down $21.5M term loan in Nov 2025.","Completed oversubscribed equity offerings raising $42.0M net; expanded commercial team.","Positive topline results from Japan trial; two institution-led studies initiated in testicular cancer and AYA patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-033885","json":"https://secwatch.observer/filing/0001104659-26-033885.json","markdown":"https://secwatch.observer/filing/0001104659-26-033885.md","text":"https://secwatch.observer/filing/0001104659-26-033885.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465926033885/0001104659-26-033885-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465926033885/fencf-20260324x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:10:04.521791+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}